95 results
8-K
EX-99.1
BLPH
Bellerophon Therapeutics, Inc.
5 Jun 23
Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
8:08am
or a placebo. The primary endpoint was the change in moderate to vigorous physical activity (MVPA) as measured by actigraphy after 16 weeks of chronic
424B5
BLPH
Bellerophon Therapeutics, Inc.
31 May 23
Prospectus supplement for primary offering
4:40pm
such as heart failure and chronic obstructive pulmonary disease (“COPD”). In December 2019, we announced top-line results from cohort 2 of the iNO-PF … , placebo-controlled, double-blind, dose-confirmation Phase 2 clinical trial of INOpulse for pulmonary hypertension associated with chronic obstructive
8-K
EX-99.1
dlsc5738b
15 May 23
Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results
4:54pm
8-K
EX-99.1
nk3vxx5hn0z
11 May 23
Pivotal top-line data readout expected in mid-2023
8:30am
8-K
EX-99.1
0zmf 34u8gj
15 Aug 22
Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results
8:41am
8-K
EX-99.1
bstfp7dc09j59
11 May 22
Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results
8:34am
8-K
EX-99.1
7u1ik8nksrl zzi
31 Mar 22
Bellerophon Provides Clinical Program Update and Reports Full-Year 2021 Financial Results
4:04pm
8-K
EX-99.1
of3 seoa30lm674dvh73
5 Jan 22
Company Presentation I January 2022Bellerophon Therapeutics
8:39am
8-K
EX-99.1
c9ds121w
17 Dec 21
Phase 2 results provide clinically meaningful reduction in pulmonary vascular resistance; Company intends to design multi-dose Phase 2b trial
8:29am
8-K
EX-99.1
amcxww zxjq
15 Nov 21
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2021 Financial Results
9:02am